Did you know that there are somewhere between 113 and 120 cannabinoids that have currently been isolated from the cannabis plant? Cannabinoids such as anandamide are endogenous cannabinoids our bodies produce, and phytocannabinoids are cannabinoids produced by the cannabis plant. Both endocannabinoids as well as phytocannabinoids work with our bodies via the endocannabinoid system. THC and CBD are two cannabinoids that you may have heard quite a lot about while CBG may not seem as familiar. They aren’t new, but research for cannabinoids was hindered by the classification of cannabis as an illegal drug. Once the 2018 Farm Bill separated cannabis with a THC content of 0.3% or less as an agricultural product we call hemp that is not on the controlled substance list and therefore legal, research began to pick up speed. CBD research came first more because of accessibility. Hemp strains were higher in CBD content therefore research naturally began with this cannabinoid. CBG is produced early in the cannabis plant’s life cycle and so by harvest time there was very little left in the plant. In fact, CBGa is often referred to as “the parent” or “stem cell” cannabinoid because the other major cannabinoid branches including CBDa, THCa and CBCa all come from CBGa. Just as cannabis varieties can contain different percentages of CBD, we are now seeing higher percentages of CBG available. Forbes magazine in 2019 noted the rarity of CBG but also highlighted its potential adding that the US government is keen on learning more about CBG and The National Center for Complementary and Integrative Health announced an intent to research as well.
So what are we learning from research about CBG? Current research has focused on uncovering properties such as anti-inflammatory, antioxidative, neuroprotective and antibacterial/fungal. Research that is evolving includes potential effects associated with depression, anxiety, bone growth, ocular pressure, overactive bladder dysfunction, inflammatory skin disorders, pain modulation and disease processes associated with the colon. An article from Cannainsider states “CBG is emerging as one of the most therapeutically diverse cannabinoids”.
Just as we have continued to learn more about CBD and how it fits in with our personal wellness journey, it is exciting to see more and more research coming our way about CBG. The science behind the endocannabinoid system will expand with it as we discover interaction pathways beyond only CB1 and CB2 to include TRPV, TRPA, alpha-2-adrenergic, 5-HT-1 and PPAR.
I look forward to the expansion of research to include many more cannabinoids to come!
This information is for general informational purposes only. It is not intended to serve as medical advice or to be any form of medical treatment and its use is at the discretion and good judgement of the reader. Consult your designated healthcare provider before changing any part of your current medical treatment including supplements, diets, and medications. Please see our website for additional information such as the FDA disclosure.